AXSM vs. NVO

In the year-to-date period, AXSM achieves a 16.42% return, which is significantly higher than NVO's -24.82% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Axsome Therapeutics, Inc. (AXSM) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current AXSM Sharpe Ratio is 0.80, which is higher than the NVO Sharpe Ratio of -1.21. The chart below compares the historical Sharpe Ratios of AXSM and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

AXSM has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 2.53%.

The maximum AXSM drawdown since its inception was -86.65%, which is greater than NVO's maximum drawdown of -71.29%. Use the drawdown chart below to compare losses from any high point for AXSM and NVO. For additional features, visit the drawdowns tool.

The current volatility for Axsome Therapeutics, Inc. (AXSM) is 13.39%, while Novo Nordisk A/S (NVO) has a volatility of 14.26%. This indicates that AXSM experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Axsome Therapeutics, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.